This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.
Lipid–arrays and live-cell imaging identify new series of sphingolipid effectors. (A) The effect of the perturbation of sphingolipid metabolism on GFP-fusion localization was monitored in yeast cells treated with myriocin, myriocin and dihydrosphingosine (DHS) or untreated (Blank). (B) The proteins-binding sphingolipids in vitro are grouped according to their sphingolipid-binding specificities, and ordered by function. The symbol # points to proteins with a PH domain. Interactions are color coded as in Figure 2, but excluding live-cell imaging. The green boxes label the proteins selected for further analysis by live-cell imaging. Those sensitive to 2 h myriocin treatments are represented with filled green boxes. For each sphingolipid-binding group, the histogram next to the matrix summarizes the overall sensitivities to myriocin. For comparison, myriocin sensitivity of 32 controls is also shown in magenta. Non-physiological lipids in S. cerevisiae are in gray and italic. DHS-1P, dihydrosphingosine-1-phosphate; PHS-1P, phytosphingosine-1-phosphate; Sph-1P, sphingosine-1-phosphate; 3-ketoDHS, 3-ketodihydrosphingosine; DHS, dihydrosphingosine; PHS, phytosphingosine; Sph, sphingosine; DHCer, dihydroceramide; PHCer C8, phytoceramide C8; PHCer C18, phytoceramide C18.